Inogen Inc (NASDAQ:INGN) Director Raymond Huggenberger sold 10,500 shares of the firm’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $196.62, for a total transaction of $2,064,510.00. Following the transaction, the director now directly owns 8,797 shares in the company, valued at $1,729,666.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Raymond Huggenberger also recently made the following trade(s):
- On Friday, September 14th, Raymond Huggenberger sold 10,500 shares of Inogen stock. The stock was sold at an average price of $282.57, for a total transaction of $2,966,985.00.
- On Wednesday, August 15th, Raymond Huggenberger sold 10,500 shares of Inogen stock. The stock was sold at an average price of $228.63, for a total transaction of $2,400,615.00.
INGN stock traded up $0.37 during mid-day trading on Wednesday, hitting $212.35. The company had a trading volume of 187,300 shares, compared to its average volume of 226,118. The firm has a market cap of $5.21 billion, a price-to-earnings ratio of 161.07, a P/E/G ratio of 4.83 and a beta of 1.26. Inogen Inc has a 12 month low of $93.23 and a 12 month high of $287.79.
Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, August 7th. The medical technology company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.44 by $0.21. The business had revenue of $97.24 million for the quarter, compared to analyst estimates of $81.61 million. Inogen had a net margin of 10.39% and a return on equity of 16.51%. As a group, analysts expect that Inogen Inc will post 2.07 earnings per share for the current year.
Hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC bought a new stake in shares of Inogen in the third quarter valued at approximately $2,063,000. NEXT Financial Group Inc bought a new stake in shares of Inogen in the third quarter valued at approximately $305,000. Copper Rock Capital Partners LLC bought a new stake in shares of Inogen in the third quarter valued at approximately $28,277,000. Hollencrest Capital Management bought a new stake in shares of Inogen in the third quarter valued at approximately $244,000. Finally, United Services Automobile Association raised its position in shares of Inogen by 19.1% in the second quarter. United Services Automobile Association now owns 3,756 shares of the medical technology company’s stock valued at $700,000 after purchasing an additional 602 shares during the period. 96.47% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have commented on INGN shares. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 20th. Piper Jaffray Companies lifted their price objective on shares of Inogen from $245.00 to $290.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 12th. Needham & Company LLC lowered shares of Inogen from a “strong-buy” rating to a “buy” rating and lifted their price objective for the stock from $254.00 to $296.00 in a research report on Monday, September 10th. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $290.00 price objective on the stock in a research report on Thursday, September 27th. Finally, Stifel Nicolaus set a $258.00 price objective on shares of Inogen and gave the stock a “buy” rating in a research report on Tuesday, August 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $247.33.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Further Reading: Day Trading
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.